POST Online Media Lite Edition



 

Teva to close plant, lay off 500 in Hungary

Staff Writer |
Reports in the Hungarian media say that Teva plans to sell or close down one of its Hungarian plants by the end of 2018.

Article continues below






The Hungarian media reported that Teva Pharmaceutical Industries would lay off 500 employees in the coming months at its plant in Godollo on the outskirts of Budapest.

Reports say that Teva plans to sell the plant or close it down by the end of 2018.

Production at the plant will continue on a smaller scale until it closes down.

At the same time, Teva is looking for a buyer for the plant, and is cooperating in this with government agencies in Hungary.

This plant made headlines in 2016, when Teva halted production there, after the US Food and Drug Administration (FDA) cited faults found there in a routine audit, and warned that it would ban imports of certain products produced there.

Teva has 2,000 more employees in its other plants in Hungary and in its sales departments in the country. These employees will be unaffected by the layoffs.


What to read next

Teva sees close of $40.5 billion Allergan generics deal by June
Teva completes £603 million sale of UK and Ireland Actavis assets
Mylan: Teva's stake buy violates U.S. anti-trust rules